Key Highlights

  • CDT Equity Inc. (NASDAQ:CDT) traded at USD 0.0905, up 13.12%, in pre-market trading on Wednesday, October 28, 2026, after its Tuesday, October 27, 2026 release on an animal health evaluation agreement with Manoira.
  • The capital update of Wednesday, September 2, 2026 cited stockholders' equity of about USD 103 million per the second quarter Form 10-Q, with a market capitalisation of about USD 23.0 million as of Monday, August 31, 2026.
  • The company holds 1,290 shares, or 22.7%, of Sarborg, which its Wednesday, October 14, 2026 release valued at about USD 161 million at the latest raise price of USD 125,000 per share.
  • The pre-market quote is a thinly traded snapshot, and a 1-for-25 reverse stock split took effect on Monday, September 28, 2026 to address the Nasdaq bid price rule.

What Lies Behind the Jump

CDT Equity Inc. (NASDAQ:CDT) develops and licenses therapeutic assets and owns an equity stake in the drug discovery company Sarborg. Shares were quoted at USD 0.0905 pre-market on Wednesday, October 28, 2026, a gain of 13.12%. A release issued at 8:00 a.m. ET on Tuesday, October 27, 2026 set the move in motion: it announced an evaluation agreement with Manoira covering the clinical-stage assets AZD1656 (including proprietary cocrystal derivatives) and AZD5904 for animal health products. Manoira is planning a launch in the first quarter of 2027, with licensing discussed only if the evaluation works out. Given the recent reverse split, a quote of USD 0.0905 is unusual and deserves caution.

How the Latest Updates Shape the Move

Because the animal health deal is an evaluation and not a licence, no financial terms were stated. In its release of Wednesday, October 14, 2026 the company flagged a Sarborg patent application and put a value of about USD 161 million on its 22.7% stake; the release of Tuesday, September 29, 2026 had cited a Sarborg fully diluted valuation of about USD 709 million. Both figures are company statements based on private raise prices. On Tuesday, September 1, 2026 CDT Equity Inc. (NASDAQ:CDT) named James Bligh chief executive, and on Tuesday, August 25, 2026 it signed a SAFE note, a convertible funding instrument, with Pep'd at a USD 10 million valuation cap. Its capital update of Wednesday, September 2, 2026 listed 13,693,866 shares outstanding ahead of the reverse split.

Bull and Bear Readings

The optimistic reading is that the Manoira deal opens an extra commercial pathway for existing assets and that the reported Sarborg stake is large relative to market capitalisation. The skeptical reading rests on the early stage of the animal health evaluation, the private and company-stated nature of the Sarborg valuation and the related-party character of the Pep'd arrangement, since the former chief executive is its sole shareholder. Specific risks include Nasdaq bid price compliance after the 1-for-25 reverse split of Monday, September 28, 2026, dilution and extreme volatility in a very low-priced stock. Watch the Federal Reserve decision due later on Wednesday, October 28, 2026, any Manoira evaluation outcome, further Sarborg financing rounds and the third quarter 2026 Form 10-Q.

Where Things Stand

CDT Equity Inc. (NASDAQ:CDT) jumped 13.12% pre-market on Wednesday, October 28, 2026, following the Manoira animal health evaluation agreement announced on Tuesday, October 27, 2026, and light trading probably amplified the move. The key figure is the USD 0.0905 pre-market price against stockholders' equity of about USD 103 million in the second quarter Form 10-Q. Upcoming items are the Federal Reserve decision later on Wednesday, October 28, 2026, Manoira evaluation results and the third quarter 2026 Form 10-Q. Pre-market readings are snapshots, and this is not investment advice.